JPMorgan Chase & Co. Reaffirms “Hold” Rating for Juno Therapeutics (JUNO)

Juno Therapeutics (NASDAQ:JUNO)‘s stock had its “hold” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

Other equities analysts also recently issued reports about the stock. SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Citigroup reaffirmed a “buy” rating and set a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Cowen reaffirmed a “buy” rating and set a $49.00 price objective on shares of Juno Therapeutics in a research report on Friday, October 27th. Maxim Group reaffirmed a “buy” rating and set a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a research report on Monday, October 9th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Monday, December 11th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Juno Therapeutics has an average rating of “Hold” and a consensus price target of $46.70.

Juno Therapeutics (JUNO) opened at $48.94 on Thursday. The firm has a market cap of $5,590.00, a price-to-earnings ratio of -14.44 and a beta of 2.32. Juno Therapeutics has a fifty-two week low of $18.90 and a fifty-two week high of $63.45. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.57) earnings per share. analysts anticipate that Juno Therapeutics will post -4.02 EPS for the current year.

In related news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at $4,395,890.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $44.76, for a total value of $391,650.00. Following the completion of the transaction, the chief financial officer now directly owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. In the last three months, insiders sold 65,956 shares of company stock valued at $3,064,378. 15.08% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of JUNO. Russell Investments Group Ltd. raised its stake in Juno Therapeutics by 64.6% in the second quarter. Russell Investments Group Ltd. now owns 17,684 shares of the biopharmaceutical company’s stock valued at $528,000 after purchasing an additional 6,943 shares in the last quarter. State of Wisconsin Investment Board raised its stake in Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after acquiring an additional 210 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Juno Therapeutics by 7.3% during the second quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after acquiring an additional 19,057 shares in the last quarter. Utah Retirement Systems raised its stake in Juno Therapeutics by 1.8% during the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after acquiring an additional 200 shares in the last quarter. Finally, Pacad Investment Ltd. acquired a new position in Juno Therapeutics during the second quarter worth about $105,000. 69.94% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2018/01/11/jpmorgan-chase-co-reaffirms-hold-rating-for-juno-therapeutics-juno.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit